Skip to main content

Table 2 Characteristics patients experiencing treatment failure after CRT

From: Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma

No.

Tumor location

Response

Time to failure

Survival

Recurrent location

Treatment after failure

1

Lt

CR

41

Deceased

LN

Chemotherapy

2

Mt

CR

30

Deceased

LN

Surgery

3

Lt

CR

30

Survive

Local

ESD

4

Mt

CR

28

Deceased

LN

Chemotherapy

5

Lt

CR

20

Survive

LN

Surgery

6

Mt

CR

20

Survive

LN

Surgery

7

Mt

CR

10

Deceased

LN

Chemotherapy

8

Mt

CR

8

Survive

Local

ESD

9

Ut

CR

8

Deceased

LN

Surgery

10

Mt

No CR

8

Deceased

Liver

Chemotherapy

11

Mt

No CR

5

Survive

LN

Surgery

12

Mt

No CR

4

Survive

Local

Surgery

13

Mt

No CR

4

Survive

Local

Surgery

14

Mt

No CR

4

Deceased

LN

Surgery

15

Mt

No CR

3

Unknown

Lung

Chemotherapy

  1. UT, upper thoracic; MT, middle thoracic; LT, lower thoracic; LN, lymph node; ESD, endoscopic submucosal dissection.